IMU-838 and Oseltamivir in the Treatment of COVID-19

Phase 2 Completed 38 enrolled University Hospitals Coventry and Warwickshire NHS Trust Immunic AG · collab MODEPHARMA Limited · collab University of Warwick · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate whether time-to-improvement is significantly better in IMU-838 plus Oseltamivir (IONIC Intervention) and standard care vs. Oseltamivir and standard care in adult subjects with coronavirus disease (COVID-19)

Timeline

Start: 2020-06-15
Primary completion: 2022-05-20
Completion: 2022-09-21

Publications

Sharma K, Berry L, Vryonis E, Ali A, Lara B, Noufaily A, Parsons N, Bradley C, Haley B, Tabuso M, Arasaradnam RP. Prospective, randomised, parallel-group, open-label study to evaluate the effectiveness and safety of IMU-838, in combination with oseltamivir, in adults with COVID-19: the IONIC trial protocol. BMJ Open. 2022 Nov 17;12(11):e055205. doi: 10.1136/bmjopen-2021-055205.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Oseltamivir	Small molecule	75 mg	—
Subject	Vidofludimus	Small molecule	22.5 mg	Oral

IMU-838 and Oseltamivir in the Treatment of COVID-19

Summary

Timeline

Publications

Drugs

Indications